Aclarion, Inc. ACON PHARMA
Company Overview
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $75.73K (+65.6% YoY); net profit $-7.23M.
- Trailing 12 Months Year-on-year growth — revenue +30.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.80% |
| 1 Year: | 30.50% |
Stock Price Performance
| 1 Year: | -65.59% |
| 6 Months: | -25.15% |
| 3 Months: | -27.38% |
| 1 Month: | +6.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACON Aclarion, Inc. PHARMA | 2.44 | -0.35 | $7.03M | 0.00% | -54.95% | -58.97% | 7.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.83K | 25.62K | 10.87K | 9.03K | 10.68K | 18.22K | 25.47K | 17.07K | 19.07K | 10.11K | 10.97K | 14.41K | - | 18.99K | 19.32K | 18.94K | 18.48K | 21.14K | 25.21K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.48K | 14.18K | 14.56K | 16.69K | 17.39K | - |
| Gross Profit | -4.74K | 5.32K | -5.22K | -7.71K | -3.57K | 1.19K | 8.02K | -2.23K | -493 | -9.36K | -12.32K | -6.92K | - | -4.49K | 5.14K | 4.39K | 1.79K | 3.75K | 8.30K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.49M | 1.74M | 1.84M | 1.99M | 2.99M | - |
| Operating Income | -460.54K | -626.62K | -797.25K | -773.10K | -2.21M | -1.63M | -1.18M | -1.41M | -1.16M | -1.28M | -1.14M | -1.30M | - | -1.49M | -1.74M | -1.83M | -1.99M | -2.99M | -2.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.44M | -1.55M | -1.65M | -1.83M | -2.93M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 271 | 0 | 0 | 0 | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.04M | -1.60M | -1.71M | -1.89M | -2.85M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -517.86K | -465.84K | -2.95M | -936.09K | -3.55M | -1.63M | -1.18M | -1.46M | -998.01K | -2.40M | -1.24M | -1.37M | - | -2.04M | -1.60M | -1.71M | -1.89M | -2.85M | -2.75M |
| Diluted EPS | - | - | -3.58 | -1.35 | -0.47 | -0.20 | -2.39 | -2.83 | -1.87 | -3,985.22 | -1,362.83 | -1,321.49 | - | -9.32 | -2.75 | -2.93 | - | -1.34 | -1.12 |
| R&D Expense | 167.75K | 162.71K | 275.28K | 204.80K | 353.23K | 290.97K | 204.40K | 250.01K | 198.25K | 239.04K | 202.10K | 195.80K | - | 198.19K | 270.43K | 302.04K | - | 315.42K | 297.07K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 60.44K | 75.40K | 45.72K | 75.73K |
| Cost of Revenue | - | 65.30K | 75.73K | 84.66K | 68.90K |
| Gross Profit | - | -4.85K | -324 | -38.93K | 6.83K |
| Operating Expenses | - | 5.56M | 4.88M | 5.47M | 7.06M |
| Operating Income | - | -5.56M | -4.88M | -5.51M | -7.05M |
| EBITDA | - | -5.42M | -4.14M | -6.26M | -7.01M |
| Interest Expense | - | 1.51M | 608.29K | 535.47K | 0 |
| Pretax Income | - | -7.07M | -4.91M | -6.99M | -7.23M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -7.07M | -4.91M | -6.99M | -7.23M |
| Diluted EPS | - | -138,594.74 | -53,971.14 | -5,151.64 | -13.61 |
| R&D Expense | 787.85K | 1.07M | 873.34K | 888.77K | 1.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.91M | 2.46M | 2.12M | 13.67M |
| Current Assets | - | - | 1.70M | 1.29M | 824.28K | 12.40M |
| Cash & Equivalents | - | - | 1.47M | 1.02M | 453.66K | 12.02M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 18.57K | 13.27K | 18.33K | 29.68K |
| Total Liabilities | - | - | 688.67K | 3.19M | 1.15M | 837.29K |
| Current Liabilities | - | - | 688.67K | 3.19M | 1.15M | 837.29K |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | 2.00M | - | 1.13M | - | - |
| Total Equity | -7.08M | - | 2.23M | -728.00K | 970.06K | 12.84M |
| Shares Outstanding | - | - | 54 | 91 | 1.37K | 854.37K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.95M | -3.65M | -5.27M | -7.16M |
| Investing Cash Flow | - | -207.87K | -119.52K | -321.94K | -203.90K |
| Financing Cash Flow | - | 6.19M | 3.31M | 5.03M | 18.95M |
| Capital Expenditure | - | -208.87K | -119.52K | -321.94K | -203.90K |
| Free Cash Flow | - | -5.16M | -3.77M | -5.59M | -7.37M |
| Net Change in Cash | - | 1.03M | -451.74K | -567.41K | 11.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -8.0% | -0.4% | -85.2% | 9.0% |
| Operating Margin % | - | -9,202.5% | -6,468.0% | -12,057.2% | -9,312.5% |
| Net Margin % | - | -11,694.4% | -6,513.4% | -15,293.8% | -9,551.9% |
| ROE % | - | -317.6% | 674.6% | -720.9% | -56.4% |
| ROCE % | - | -249.9% | 669.9% | -568.3% | -54.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bridgeway Capital Management, LLC | 0.68% | 19.48K | $49.09K |
| 2 | CAPTRUST Financial Advisors | 0.59% | 17.06K | $42.99K |
| 3 | Vanguard Fiduciary Trust Co | 0.56% | 16.03K | $40.39K |
| 4 | Susquehanna International Group, LLP | 0.53% | 15.36K | $38.69K |
| 5 | Geode Capital Management, LLC | 0.42% | 12.13K | $30.56K |
| 6 | Xtx Topco Ltd | 0.38% | 11.04K | $27.82K |
| 7 | Bank of Montreal /CAN/ | 0.35% | 10.00K | $25.20K |
| 8 | Vanguard Capital Management LLC | 0.24% | 6.78K | $17.09K |
| 9 | Osaic Holdings Inc. | 0.17% | 5.00K | $12.60K |
| 10 | UBS Group AG | 0.07% | 1.97K | $4.96K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACON
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovationTen sites now activel…
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging cen…
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Aclarion (ACON) delivered earnings and revenue surprises of -6.67% and -15.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan v…
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence …
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence …
ACON — Frequently Asked Questions
What is the current share price of Aclarion, Inc. (ACON)?
As of 2026-09-19 21:16 PDT, Aclarion, Inc. (ACON) trades at $2.44 on NasdaqCM. Its 52-week range is $2.02 to $9.69.
What is the market capitalisation of ACON?
Aclarion, Inc. (ACON) has a market capitalisation of $7.03M on NasdaqCM.
What is the P/E ratio of ACON?
ACON trades at a trailing price-to-earnings (P/E) ratio of -0.35. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.35.
What is the return on equity (ROE) of ACON?
ACON has a return on equity (ROE) of -58.97%. Its return on capital employed (ROCE) is -54.95%.
Is ACON a good stock to buy?
This page provides a data-driven analysis of Aclarion, Inc. (ACON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.